ARYx Therapeutics
closedPharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases.
Launch date
Employees
Market cap
AUD367k
Enterprise valuation
AUD367k (Public information from Sep 2024)
Share price
$0.0005 ARYX
Fremont California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$25.0m | Series C | ||
$55.0m | Series D | ||
$30.4m | Series E | ||
N/A | N/A | IPO | |
$21.6m | Private Placement VC | ||
$360k | Post IPO Equity | ||
$6.3m | Debt | ||
Total Funding | AUD204m |